NAARDEN, Netherlands--(BUSINESS WIRE)--Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the initiation of a double blind, placebo controlled, Phase 2b dose ranging study of DEZ-001 (previously TA-8995), alone and in combination with statins, in order to study the effects on a wide range of lipids and other biomarkers of cardiovascular disease (CVD) in patients with mild dyslipidemia.
Help employers find you! Check out all the jobs and post your resume.
